Varelas Christos, Gavriilaki Eleni, Sakellari Ioanna, Klonizakis Philippos, Koravou Evaggelia-Evdoxia, Christodoulou Ioanna, Mavrikou Ioulia, Kourelis Andreas, Chatzopoulou Fani, Chatzidimitriou Dimitrios, Touloumenidou Tasoula, Papalexandri Apostolia, Anagnostopoulos Achilles, Vlachaki Efthimia
Hematology & BMT Unit, General Hospital "George Papanikolaou", 57010 Thessaloniki, Greece.
Adult Thalassaemia Unit, 2nd Department of Internal Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital, 54124 Thessaloniki, Greece.
J Clin Med. 2022 Feb 11;11(4):937. doi: 10.3390/jcm11040937.
Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are essential weapons to control the spread of the coronavirus disease-19 (COVID-19) pandemic and protect immunocompromised patients. With a greater susceptibility to infection, sickle cell disease (SCD) patients are considered as "high risk" patients during the current COVID-19 pandemic. In our study, we try to determine the immune response of adult SCD patients monitored at our center after the first and second dose of the qualified mRNA vaccines available and correlate them to several disease-specific markers, as well as complement activation. The results demonstrate that the levels of neutralizing antibodies (nAbs) against SARS-CoV-2 were adequate for most patients studied after the second dose and there seemed to be a certain association with complement activation. Further studies are critical to determine the durability of this immune response and the potential benefit of a third dose.
针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的疫苗是控制冠状病毒病19（COVID-19）大流行传播和保护免疫功能低下患者的重要武器。镰状细胞病（SCD）患者感染易感性更高，在当前COVID-19大流行期间被视为“高危”患者。在我们的研究中，我们试图确定在我们中心接受监测的成年SCD患者在接种首剂和第二剂合格mRNA疫苗后的免疫反应，并将其与几种疾病特异性标志物以及补体激活相关联。结果表明，大多数研究患者在接种第二剂疫苗后，针对SARS-CoV-2的中和抗体（nAbs）水平足够，并且似乎与补体激活存在一定关联。进一步的研究对于确定这种免疫反应的持久性以及第三剂疫苗的潜在益处至关重要。
